|
| 1） |
Stamey TA, Kabalin JN, McNeal JE, et al. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients. J Urol. 1989;141（5）:1076-83. |
| 2） |
Schild SE, Wong WW, Novicki DE, et al. Detection of residual prostate cancer after radical prostatectomy with the Abbott IMx PSA assay. Urology. 1996;47（6）:878-81. |
| 3） |
Oefelein MG, Smith N, Carter M, et al. The incidence of prostate cancer progression with undetectable serum prostate specific antigen in a series of 394 radical prostatectomies. J Urol. 1995;154（6）:2128-31. |
| 4） |
Pound CR, Partin AW, Eisenberger MA, et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;281（17）:1591-7. |
| 5） |
Scher HI. Management of prostate cancer after prostatectomy:treating the patient, not the PSA. JAMA. 1999;281（17）:1642-5. |
| 6） |
D'Amico AV, Moul JW, Carroll PR, et al. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst. 2003;95（18）:1376-83. |
| 7） |
D'Amico AV. Predicting prostate-specific antigen recurrence established:now, who will survive? J Clin Oncol. 2002;20（15）:3188-90. |
| 8） |
Iselin CE, Robertson JE, Paulson DF. Radical perineal prostatectomy:oncological outcome during a 20-year period. J Urol. 1999;161（1）:163-8. |
新検索ページはこちら
ログイン
お問い合わせ
書誌情報
引用文献
